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BACKGROUND: Non-invasive diagnostic strategies aimed at identifying biomarkers of cancer are of great interest for early cancer
detection. Urine is potentially a rich source of volatile organic metabolites (VOMs) that can be used as potential cancer biomarkers.
Our aim was to develop a generally reliable, rapid, sensitive, and robust analytical method for screening large numbers of urine
samples, resulting in a broad spectrum of native VOMs, as a tool to evaluate the potential of these metabolites in the early diagnosis
of cancer.
METHODS: To investigate urinary volatile metabolites as potential cancer biomarkers, urine samples from 33 cancer patients
(oncological group: 14 leukaemia, 12 colorectal and 7 lymphoma) and 21 healthy (control group, cancer-free) individuals were
qualitatively and quantitatively analysed. Dynamic solid-phase microextraction in headspace mode (dHS-SPME) using a carboxen-
polydimethylsiloxane (CAR/PDMS) sorbent in combination with GC-qMS-based metabolomics was applied to isolate and identify
the volatile metabolites. This method provides a potential non-invasive method for early cancer diagnosis as a first approach. To fulfil
this objective, three important dHS-SPME experimental parameters that influence extraction efficiency (fibre coating, extraction time
and temperature of sampling) were optimised using a univariate optimisation design. The highest extraction efficiency was obtained
when sampling was performed at 501C for 60min using samples with high ionic strengths (17% sodium chloride, w v1) and under
agitation.
RESULTS: A total of 82 volatile metabolites belonging to distinct chemical classes were identified in the control and oncological groups.
Benzene derivatives, terpenoids and phenols were the most common classes for the oncological group, whereas ketones and sulphur
compounds were the main classes that were isolated from the urine headspace of healthy subjects. The results demonstrate that
compound concentrations were dramatically different between cancer patients and healthy volunteers. The positive rates of 16
patients among the 82 identified were found to be statistically different (Po0.05). A significant increase in the peak area of 2-methyl-
3-phenyl-2-propenal, p-cymene, anisole, 4-methyl-phenol and 1,2-dihydro-1,1,6-trimethyl-naphthalene in cancer patients was
observed. On average, statistically significant lower abundances of dimethyl disulphide were found in cancer patients.
CONCLUSIONS: Gas chromatographic peak areas were submitted to multivariate analysis (principal component analysis and supervised
linear discriminant analysis) to visualise clusters within cases and to detect the volatile metabolites that are able to differentiate cancer
patients from healthy individuals. Very good discrimination within cancer groups and between cancer and control groups was
achieved.
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Cancer is characterised by abnormal growth and development of
normal cells beyond their natural boundaries. Despite global
efforts to limit the incidence of this disease, cancer has become the
leading cause of death in the last 50 years. Specifically, breast
cancer is the most common malignancy and the second most
common cause of cancer-related mortality in women. Prostate
cancer is the most common solid organ malignancy diagnosed in
men in Europe and the United States of America and is the second
most frequent cause of cancer-related death in men (Ullah and
Aatif, 2009; Jemal et al, 2010). Furthermore, after cardiovascular
diseases, cancer is the second cause of death among the global
population (Infante et al, 1994; Weisburger and Williams, 2000;
Oliveira et al, 2007).
The factors that are responsible for cancer development are
classified as exogenous and endogenous (Oliveira et al, 2007). The
first group includes nutritional habits (food preservation and
preparation), socio-economic status, lifestyle, physical agents
(ionising and non-ionising radiation), chemical compounds
(natural and synthetic) and biological agents (Helicobacter pylori,
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Epstein–Barr virus, human T lymphotropic viruses I and II,
human papilloma virus and the hepatitis B virus, as well as
parasites, such as Schistosoma haemotobium, Clonorchis sinensis
and Opisthorchis vivarium) (Minamoto et al, 2000; Weisburger and
Williams, 2000). Unhealthy lifestyle habits such as excess alcohol
consumption, the inhalation of tobacco and related products, the
ingestion of certain foods and their contamination by mycotoxins
are responsible for higher incidences of certain types of neoplasias
in a number of population groups (Weisburger and Williams,
2000; Oliveira et al, 2007). Endogenous factors include immune
system damage and inflammation caused by uncertain aetiology
(e.g., ulcerative colitis and pancreatitis), genetic makeup, age,
endocrine balance and physiological condition (Barrett and
Anderson, 1993; Infante et al, 1994).
The management of high-risk cancers requires diagnosis at an
early stage, which specifies the need for specific and sensitive
biomarkers. Sometimes, certain molecules are differentially
expressed in cancer cells relative to their normal counterparts,
and their altered levels can be measured to establish a correlation
with the diseased state (Cassiday, 2006; Jemal et al, 2010). With the
development of high-throughput techniques for biomarker dis-
covery, the field of cancer biomarkers has rapidly expanded
(Lauridsen et al, 2007; Gramolini et al, 2008; Gaspar and Lopes,
2009; Jiang and Ma, 2009; Matsumura et al, 2010). Current
biomarker candidates from blood, sputum and urine include many
classes of molecules, such as proteins, tumour-specific antigens,
anti-tumour antibodies, cell type-specific peptides, various meta-
bolic products and epigenetic phenomena (e.g., hyper-methylated
DNA, RNA and specific gene expression) (Greenberg and Lee,
2007; Matsumura et al, 2010); however, according to Matsumura
et al (2010), no biomarker identified to date has been shown to
have adequate sensitivity, specificity and reproducibility so as
to be considered sufficient for use in the detection and monitoring
of lung cancer development.
One promising class of biomarkers for cancer could be low-
molecular-weight volatile organic metabolites (VOMs) (Matsu-
mura et al, 2010). The ‘volatile hypothesis’, which was initially
postulated for lung cancer, has led to a number of studies
examining the utility of analysing these metabolites in the exhaled
breath of animals (such as dogs) or in sophisticated biochemical
techniques (McCulloch et al, 2006; Belda-Iniesta et al, 2007; Song
et al, 2010). Thousands of VOMs are present in trace amounts in
human breath, and different studies have shown that VOM profiles
of patients with lung cancer can be discriminated from those of
healthy subjects (Phillips et al, 2003, 2006; Mazzone, 2008; Yung,
2010). A recent study from the Chen group using solid-phase
micro-extraction (SPME) followed by gas chromatography (GC)
has demonstrated that 1-butanol and 3-hydroxy-2-butanone
were found at significantly higher concentrations in the breath of
lung cancer patients in comparison with the controls (Chen
et al, 2007).
To date, current screening trials have primarily focused on
imaging modalities, such as computer tomography, magnetic
resonance imaging, endoscopy and ultrasonography, together with
clinical analysis; however, these methods are time-consuming and
unpleasant for patients and require skilled medical staff and
expensive devices. Over the past few years, however, non-imaging
methods have been investigated.
Urine and breath analysis for the routine monitoring
of metabolic disorders has attracted a considerable amount of
scientific interest, especially because their sampling is
non-invasive. These types of analyses are totally painless and
agreeable to patients and can be performed as often as needed.
Apart from providing the possibility of non-invasive diagnostic
testing, urine has other advantages over breath, serum or
cerebrospinal fluid (Deng et al, 2004b; Xue et al, 2008). Most
important, many metabolites occur in urine at nearly the same
concentrations as in the plasma, whereas the total volatile
metabolites in the plasma are relatively low (mg–ng l1). Thus,
the relative enrichment of volatile components makes urine an
attractive target for a volatile metabolomic profiling approach.
Urinary metabolomic studies have already been applied to the
breast (Chen et al, 2009; Henneges et al, 2009), lung (Carrola et al,
2011), prostate (Chikkaveeraiah et al, 2009; Sreekumar et al, 2009;
Jentzmik et al, 2010), colorectal (Ma et al, 2009; Qiu et al, 2010)
and liver cancers (Chen et al, 2009).
In recent years, there has been an enormous effort to develop
specific and sensitive biomarkers for the precise and accurate
screening, diagnosis, prognosis and monitoring of high-risk cancer
to assist with therapeutic decisions. Different methods have thus
been developed to analyse volatile metabolites and compare them
in healthy subjects and cancer patients, such as chemical
interaction, adsorptive binding, cold trapping and supercritical
fluid extraction. The most successful methods in this field are
SPME and the recently developed multi-bed sorption trap
(Giardina and Olesik, 2003; Prado et al, 2003; Yu et al, 2009).
This technique was developed by Pawliszyn in late 1989 as a new
pre-concentration technology in which a fused coated silica fibre is
used as the stationary phase (Ouyang et al, 2005; Song et al, 2010).
This methodology presents several advantages over conventional
solvent extraction procedures: SPME is rapid, easy to use,
solvent free and sensitive, and does not require any concen-
tration step before analysis, preventing artefacts (Musteata and
Pawliszyn, 2007).
Therefore, in this study, we tested the potentialities of a simple
and solvent-free miniaturised high-throughput analytical metho-
dology without sample derivatisation based on dynamic solid-
phase microextraction in headspace mode (dHS-SPME) in
combination with GC-qMS. This technique was used for the
metabolomic analysis of urine samples that were obtained from
clinically diagnosed patients with leukaemia, colorectal and
lymphoma cancers, and from healthy controls (cancer-free) to
provide comprehensive information on volatile metabolites as
potential cancer biomarkers.
A comparative analysis of the urine metabolome between cancer
patients and normal controls was carried out. This study presents
some preliminary results in a small group of cancer patients in
comparison with the controls. Six different stationary phases,
polydimethylsiloxane (PDMS), polyacrylate (PA), divinylbenzene/
carboxen/PDMS (DVB/CAR/PDMS), carbowax/DVB (CW/DVB),
CAR/PDMS and PDMS/DVB, providing specificity for a wide range
of polar and non-polar volatile compounds, were compared in
terms of extraction efficiency and sensitivity. Factors that might
affect the dHS-SPME procedure, such as extraction time and
extraction temperature, were also investigated to determine the
analytical performance of the selected fibre.
To test the applicability of our method, a total of 54 urine
samples (healthy individuals, n¼ 21 and cancer patients, n¼ 33)
were collected in the Hospital Dr Ne´lio Mendonc¸a (Haemato-
Oncology Unit) and analysed. Multivariate statistical methods were
used to gain insight into the metabolomic differences between
healthy and patient cases and find related volatile metabolites that
could be associated with a unique type of cancer (e.g., leukaemia,
colorectal, lymphoma). This identification is indispensable for
future work on the biochemical sources of these compounds and
their metabolic pathways.
MATERIALS AND METHODS
Reagents and materials
Sodium chloride (NaCl) and hydrogen chloride (HCl) were
purchased from Panreac (Barcelona, Spain) and Sigma-Aldrich
(St Louis, MO, USA), respectively. Ultra-pure water from a Milli-Q
system (Millipore, Bedford, MA, USA) with a conductivity of
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18MO was used throughout. Helium at a purity of 99.999% (Air
Liquide, Lisbon, Portugal) was utilised as the GC carrier gas. A
Cimarec digital stirring hot plate was supplied by Thermo
Scientific (Waltham, MA, USA). The SPME holder for manual
sampling of SPME fibres and glass vials was purchased from
Supelco (Bellefonte, PA, USA). The SPME fibres were conditioned
as recommended by the manufacturer, but below the maximum
recommended temperature before their first use. Before the first
daily analysis, the fibres were conditioned for 5min at the
operating temperature of the GC injector port and the blank level
was checked. The analyses were performed in triplicate.
Subjects and sample collection
The subjects were divided into four groups: normal controls and
cancer patients with leukaemia, colorectal and lymphoma
(Table 1). Normal controls (n¼ 21, age¼ 44.2±10.3 (range 28–60)
years, 18 male and 3 female) volunteered and were eligible to
participate in the study if they were 18 years of age or older and
had no previously diagnosed cancer.
The subjects were selected from among the blood donors at the
Hospital Dr Ne´lio Mendonc¸a (Funchal, Portugal). Urine samples
were collected at the Blood Bank of Funchal Hospital. In all, 33
urine specimens from patients with different cancer pathologies
(oncological group) were collected at the Unit of Haematology–
Oncology at the same institution. Leukaemia (n¼ 14,
age¼ 50.1±12.4 (40–74) years, 6 male and 8 female), colorectal
cancer (n¼ 11, age¼ 62.0±11.7 (49–78) years, 8 male and 3
female) and lymphoma (n¼ 7, age¼ 42.0±19.1 (18–68) years,
6 male and 1 female) patients were identified using specific
examinations. As can be observed from these data, the groups
were small and not balanced. Each individual (either patient or
healthy volunteer) provided a sample of morning urine (after
overnight fasting) in a 20ml sterile PVC container. The samples
were frozen at 801C and retained until needed for the
experiments. Before extraction, the pH values of the 25ml urine
samples were adjusted to 1–2.
All subjects signed an informed consent to participate in the
study, and the research was approved by the Ethics Committee of
Funchal Hospital.
dHS-SPME procedure
The development of a suitable dHS-SPME method to establish a
urinary volatile metabolomic profile from cancer patients and
healthy volunteers involved the selection and optimisation of
multiple parameters that influenced extraction. In particular, the
nature of the adsorptive phase, the sampling temperature and the
extraction time required to achieve equilibration between the
analytes and the fibre were considered by applying a univariate
experimental design.
Fibre selection was performed by testing and comparing the
extraction efficiency of six SPME fibres (Supelco) to different
stationary phases and various film thicknesses, including PDMS
(100mm), PA (85 mm), DVB/CAR/PDMS (50/30 mm), CAR/PDMS
(75mm), CW/DVB (70mm) and PDMS/DVB (65 mm). A urine
sample from a normal subject was used as the matrix for the
optimisation of the dHS-SPME parameters. Frozen urine samples
were completely thawed at room temperature before use.
For dHS-SPME optimisation, 4ml aliquots of urine samples that
had been adjusted to a pH of 1–2 with 50ml of 5.0 M HCl were
placed in an 8-ml headspace glass vial. After the addition of 0.8 g of
NaCl and stirring (0.5 0.1-mm bar) at 800 r.p.m., the vial was
capped with a Teflon (PTFE) septum and an aluminium cap
(Chromacol, Hertfordshire, UK).
The addition of salt greatly increased the extraction efficiency
for many of the metabolites, particularly the polar ones. The
presence of salt can influence adsorption in two ways: by changing
the properties of the phase boundary and decreasing the solubility
of hydrophilic metabolites in the aqueous phase (salting-out
effect). This salting-out effect is widely used to increase the
sensitivities of analytical methodologies.
The sample vial was placed in a thermostat bath that was
adjusted to 50.0±0.11C and then the SPME fibre was inserted into
the headspace for 60min. After sampling, the SPME fibre was
withdrawn into the needle, removed from the vial and inserted into
the injector port (2501C) of the GC-qMS system for 6min, wherein
the metabolites were thermally desorbed and transferred directly
to the analytical column. Each sample was analysed in triplicate.
Blanks, which corresponded to analyses of coating fibres that were
not submitted to any extraction procedure, were run between
sets of three analyses. A CAR/PDMS fibre was used to investigate
the extraction temperature and time. Extraction was performed
at temperatures of 301C, 501C and 601C for 30, 45, 60 and
75min with a stirring rate of 800 r.p.m. The optimum conditions
were determined by the sum of the peak areas obtained
under each parameter, number of extracted metabolites and
reproducibility.
GC-qMS analysis
The SPME fibre with absorbed/adsorbed (depended on the fibre
coating) volatile metabolites was inserted into the injection port of
an Agilent Technologies 6890N Network gas chromatograph
system (Palo Alto, CA, USA), and metabolites were desorbed
for 6min at 2501C. The gas chromatograph was equipped with
a 30m 0.25mm ID 0.25 mm film thickness BP-20 (SGE,
Dortmund, Germany) fused silica capillary column and interfaced
with an Agilent 5975 quadrupole inert mass selective detector. We
employed the following chromatographic protocol for separation
before the MS analyses: 351C for 2min, and then programmed at
2.51Cmin1 to 2201C with a 5-min hold at this final temperature,
for a total GC run time of 77min. The column flow was maintained
constant at 1mlmin1 using He (Helium N60, Air Liquide) as the
carrier gas. The injection port was operated in the splitless mode
and held at 2501C.
For the 5975MS system, the operating temperatures of the
transfer line, quadrupole and ionisation source were 270, 150 and
2301C, respectively. Electron impact mass spectra were recorded at
a 70 eV ionisation voltage and the ionisation current was 10 mA.
The acquisitions were performed in Scan mode (30–300 m/z), and
the electron multiplier was set to the autotune procedure.
Metabolite identification was accomplished through manual
interpretation of spectra and matching against the Agilent MS
ChemStation Software (Palo Alto, CA, USA) or commercially
available standard samples, when available. This software was
equipped with an NIST05 mass spectral library with a similarity
threshold of 480%. A series of C8–C20 n-alkanes were analysed
using the same methodology (dHS-SPMECAR/PDMS/GC-qMS) to
establish the retention indices and to confirm the identity of the
metabolites via comparison with the literature.
Table 1 The characteristics of subjects
Patients
Colon Leukaemia Lymphoma
Normal
controls
Number 11 14 7 21
Mean age (s.d.) 62.0 (11.7) 50.1 (12.4) 42.0 (19.1) 44.1 (10.3)
Gender (male/female) 8/3 6/8 6/1 18/3
Current smokers 0 0 2 3
Ex-smokers 0 0 1 0
Abbreviation: s.d.¼ standard deviation.
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Statistical analysis
Data statistical analysis was performed using the SPSS 17.0
package for Windows (SPSS Inc., Chicago, IL, USA). Significant
differences among the groups were assessed with a one-way
analysis of variance (ANOVA). The least square difference (LSD)
test (P-value o0.05) was used to compare the means. Principal
component analysis (PCA) was also applied to the analysed groups
to verify the distribution of the variables for the referred groups.
RESULTS AND DISCUSSION
The sequence followed in this study consisted of two steps. The
first focused on obtaining the best experimental conditions to
extract volatile metabolites from the urine of healthy and cancer
volunteers using dHS-SPME. In the second step, an objective
comparison of the metabolomic patterns found in the urine from
cancer patients and healthy volunteers was established in terms of
qualitative (identification by comparing the MS spectrum with the
ko´vats index) and semiquantitative (peak area ratio) differences
under optimised conditions. Different profiles for healthy people
and cancer patients were successfully recognised. Among other
compound classes, aldehydes, ketones, terpenoids, acids, furans,
volatile phenols, benzene derivatives, sulphur-containing com-
pounds and naphthalenes were identified.
Optimisation of the dHS-SPME parameters
The optimisation of the different parameters involved in HS-SPME
was performed by choosing the conditions that achieved the
maximum response in terms of metabolite peak area, number of
detected metabolites and reproducibility.
Fibre selection
As far as selection of the SPME fibre was concerned, the nature of
the metabolites influenced which SPME fibre was chosen. There-
fore, six SPME fibres were tested to select the most appropriate to
isolate volatile metabolites from urine. The results of the relative
extraction efficiency for the tested fibres are shown in Figure 1A.
By comparing all of the tested fibres in terms of chromato-
graphic areas, the number of identified metabolites and relative
standard deviation (r.s.d.), the best efficiency was obtained using a
CAR/PDMS coating, whereas the lowest efficiency was obtained
using the PDMS and PA fibres. Each extraction was performed in
triplicate and the repeatability (% r.s.d.) was lower than 20%.
Thus, the CAR/PDMS fibre (Figure 1A) was chosen as the SPME
fibre for the remaining optimisation studies.
Extraction temperature and time
Using an extraction time of 60min with 4ml of the same urine
sample, the effect of extraction temperature at 30, 50 and 601C on
SPME extraction efficiency was investigated. The volatile metabo-
lites were extracted under acidic (pH 1–2) conditions using only
the CAR/PDMS fibre. The plot of the peak areas vs extraction
temperatures is shown in Figure 1B.
Temperature will substantially affect the diffusion rates of
VOMs. Raising the temperature progressively from 30 to 501C
increased the number of extracted metabolites that were identified.
Although there was a slight increase in the number of metabolites
that were identified at 601C (2 more), the r.s.d. obtained therein
was higher than those for the other investigated temperatures. At
high temperatures (above 501C), there is a probable degradation of
the sample; hence, 501C was used for the remainder of the study.
As outlined in Figure 1B, the temperature was fixed at 501C for the
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Figure 1 Optimisation of the solid-phase micro-extraction (SPME) influencing extraction parameters: (A) effect of fibre coatings (60min of extraction
time at 501C); (B) effect of extraction temperature (fibre: 75 mm carboxen-polydimethylsiloxane (CAR/PDMS); extraction time: 60min); and (C) influence
of the extraction time (fibre: 75 mm CAR/PDMS; extraction temperature: 501C) on SPME extraction efficiency of urinary volatile metabolites in a healthy
individual. All assays were carried out with continuous stirring (800 r.p.m.). Thermal desorption of metabolites were performed at 2501C for 6min. Numbers
above the bars represent the total number of metabolites identified.
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polydimethylsiloxane (CAR/PDMS) coating exposed to the headspace vapour for 60min at 501C. Peak identification: (1) methanethiol; (2) acetone;
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(10) linalool oxide; (11) 2-ethyl-1-hexanol; (12) vitispirane I; (13) menthol; (14) 4,7-dimethyl-benzofuran; (15) 1,2-dihydro-1,1,6-trimethyl-naphthalene;
(16) b-damascenone; (17) p-cimenol; (18) 3,4-dimethyl-benzaldehyde; (19) 1-ethyl-3,5-diisopropyl-benzene; (20) 4-methyl-phenol; (21) p-tert-butyl-phenol;
and (22) 2,4-bis(1,1-dimethylethyl)-phenol.
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Figure 3 Comparison between healthy and oncological group of four illustrative metabolites selected from 82 peaks analysed. Enlarged part of the
chromatograms of Figure 2 with peaks representing: (A) dimethyl disulphide (ion 94); (B) hexanal (ion 44); (C) 3-heptanone (ion 57); and (D) 2-methyl-3-
phenyl-2-propenal (ion 145).
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extraction of urinary volatile metabolites from healthy volunteers
and cancer patients.
The influence of extraction time on the efficiency of the SPME
process was investigated by exposing the SPME fibre to the urine
headspace at 501C for 30, 45, 60 and 75min. Sorption time profiles
for volatile metabolites indicated that a sampling time of445min
was necessary to reach equilibrium. When the equilibrium was not
reached, an alternative methodology was to develop the extraction
under non-equilibrium conditions, which require shorter extrac-
tion times. Figure 1C demonstrates that the equilibrium between
the samples and fibre was established in 60min. With additional
extraction time, there was no obvious increase in the peak area. On
the basis of the results, 60min was chosen as the extraction time
for further analysis.
Characterisation and comparative analysis of urinary
volatile metabolites
We next characterised the nature of the chemical variation in the
collected urine samples to distinguish individuals with tumours
from those without by analysing urinary volatile metabolites using
solid-phase microextraction in combination with GC coupled to
mass spectrometry. According to the typical GC-qMS total ion
chromatograms (TICs) depicted in Figure 2, a large and diverse set
of metabolites can be distinguished in the urine obtained from
healthy people (control group) and that obtained from cancer
patients (leukaemia, colorectal and lymphoma).
Different urinary GC-qMS profiles for healthy people and cancer
patients were able to be recognised. In all, 82 of the identified
volatile metabolites that were found in both the cancer and the
healthy urine samples included a variety of chemical structures
and were identified to be involved in multiple biological functions
(e.g., pheromonal communication for 2-heptanone; Deng et al
(2004a)). Some metabolites that have previously been reported to
appear in human urine (dimethyl disulphide, methanethiol and
2-methylbutanoic acid) (Henneges et al, 2009) were also identified.
The enlarged peaks in the TICs of some of the significant
metabolites are depicted in Figure 3, and these facilitate the
differentiation of metabolomic profiles.
The peak area ranges (minimum, maximum and median values)
of the urinary volatile metabolites that were found in the cancer
patients and healthy subjects are summarised in Supplementary
Table 1. Identification was performed using a NIST05 library
through comparison of fragmentation patterns with a standard
mass chromatogram and verified by reference compounds, where
available.
The metabolomic origin and physiological function of most of the
VOMs are still not known. Their origins lie in a variety of
endogenous biochemical pathways and exogenous sources (environ-
mental, unhealthy lifestyle habits, biological agents); however, the
chemical pathways of generation have not yet been explained. Some
of the endogenous markers were derived from the mevalonic acid
pathway of cholesterol synthesis (e.g., unsaturated hydrocarbons like
isoprene), from glucose metabolism (e.g., acetone) and from the
oxygen free radical-mediated lipid peroxidation of fatty acids
(e.g., aldehydes and linear and branched saturated hydrocarbons). The
source of the VOMs that was identified to derive from naphthalene is
not yet known; they may be the degradation products of steroids.
Further research would be required to determine which of these
metabolites are of tumour origin and which originate from normal
metabolic processes, as well as which are down- or upregulated by
tumour growth.
Variation in the peak areas of identified metabolites clearly
showed differences in the relative amounts of various metabolites
for different individuals (Supplementary Table 1 and Figure 4A
and B). The identified metabolites belonged to several distinct
chemical families: aldehydes, ketones, terpenoids, acids, alcohols,
benzene derivatives, furan and sulphur-containing compounds,
phenols, esters, naphthalene derivatives and miscellaneous
(Figure 4A).
We observed relatively consistent changes for many metabolites
in samples obtained from the cancer group, with the most
common pattern being decreased production (downregulation) in
the cancer group samples and either increased production
(upregulation) or a negligible change in the control group. For
example, volatile sulphur-containing metabolites such as dimethyl
disulphide, methanethiol, dimethyl trisulphide and methoxythio-
phene, which are generated in humans by the incomplete
metabolism of methionine in the transamination pathway, were
dramatically downregulated as a consequence of neoplastic cell
presence (Supplementary Table 1). Thus, an overall downregula-
tion of these metabolites may be a common feature of tumour
growth.
For the control group, the largest chemical classes in the
metabolomic profile were ketones, sulphur compounds, volatile
phenols and terpenoids. The major metabolites of these chemical
families are 4-heptanone, dimethyl disulphide, p-tert-butyl phenol
and D-carvone, respectively. The origin of 4-heptanone is still
unknown, but it is probably from an exogenous source (Deng et al,
2004b). It has previously been reported that 4-heptanone is
produced from the in vivo metabolism of plasticisers in humans
(Walker and Mills, 2001). Esters and higher alcohols were the
chemical classes with the smallest contributions to the volatile
metabolomic profile.
Ketones, volatile phenols, terpenoids and benzene derivatives
were the chemical groups that contributed most to the
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Figure 4 Average levels of metabolites excreted in urine samples from
normal subjects (21) and cancer patients (31). (A) Chemical families
identified in oncological and control groups (Ald – aldehydes; Ket –
ketones; BD – benzene derivates; Terp – terpenoids; Ac – acids; FC – furan
compounds; SC – sulphur compounds; VP – volatile phenols; Est – esters;
HA – higher alcohols; ND – naphthalene derivates; Misc – miscellaneous).
(B) Average areas for statistically significant metabolites identified in cancer
patients. Numbered bars correspond to: (1) hexanal; (2) heptanal; (3) 2-
methyl-3-phenyl-2-propenal; (4) 3-heptanone; (5) 1,2,4-trimethylbenzene;
(6) p-cymene; (7) anisole; (8) g-terpinene; (9) bornylene; (10) dimethyl
disulphide; (11) 2-methoxythiophene; (12) 4-methyl-phenol; (13)
1-octanol; (14) 1,2-dihydro-1,1,6-trimethyl-naphthalene; (15) 1,4,5-tri-
methyl-naphthalene; and (16) 2,7-dimethyl-quinoline.
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Table 2 Identification mode, fragment ion m/z with the highest abundance match percentage to the NIST library and the frequency of occurrence of the
identified metabolites in patients and normal controls
Frequency of occurrence (%)
Metabolites IDa m/z Match per cent Colorectal Leukaemia Lymphoma Control
Methanethiolb MS 47 80 100.0c 100.0 100.0 100.0
Furanb St, MS 68 91 100.0 100.0 100.0 100.0
Acetoneb St, MS 43 80 100.0 100.0 100.0 100.0
2-Methylfuranb MS 82 87 100.0 100.0 100.0 100.0
Ethyl acetate St, MS 43 85 33.3 71.4 71.4 71.4
2-Butanoneb St, MS 43 82 100.0 100.0 100.0 100.0
2-Methyl-butanal MS 57 87 33.3 42.9 57.1 71.4
3-Methyl-butanal St, MS 44 81 33.3 7.1 14.3 28.6
2,5-Dimethyl-furan MS 96 85 91.7 100.0 100.0 100.0
2-Pentanoneb St, MS 43 86 100.0 100.0 100.0 100.0
Methyl isobutyl ketone St, MS 43 93 41.7 71.4 71.4 100.0
Toluene St, MS 91 86 91.7 100.0 85.7 100.0
1-(2-furanyl)ethanoneb St, MS 95 80 100.0 100.0 100.0 100.0
Dimethyl disulphideb St, MS 94 97 100.0 100.0 100.0 100.0
3-Hexanoneb St, MS 43 84 100.0 100.0 100.0 100.0
Hexanalb St, MS 44 90 100.0 100.0 100.0 100.0
Geraniol oxide MS 139 90 41.7 57.1 57.1 90.5
4-Heptanoneb St, MS 71 91 100.0 100.0 100.0 100.0
p-Xylene MS 91 88 16.7 21.4 42.9 NF
3-Heptanone St, MS 57 89 NF NF 57.1 95.2
a-Terpinene St, MS 121 95 75.0 85.7 71.4 52.4
1,4-Cineol St, MS 111 87 58.3 78.6 85.7 61.9
Limonene St, MS 68 84 33.3 57.1 57.1 28.6
2-Heptanone St, MS 43 83 91.7 92.9 85.7 100.0
Heptanal St, MS 44 80 91.7 NF 14.3 95.2
4-Methyl-2-heptanone MS 43 80 84.0 NF NF 19.4
g-Terpinene St, MS 93 89 58.3 92.9 100.0 57.1
m-Cymeneb MS 119 97 100.0 100.0 100.0 100.0
2,2,6-Trimethyl-cyclohexanone MS 82 88 41.7 71.4 42.9 76.2
2-Methoxythiophene MS 114 89 100.0 92.9 100.0 100.0
1,2,4-Trimethylbenzene MS 105 90 83.3 85.7 100.0 95.2
Dimethyl trisulphide St, MS 126 91 83.3 100.0 100.0 100.0
2-Methyl-5-(methylthio)furan MS 128 91 91.7 92.9 85.7 100.0
Nonanal St, MS 57 80 83.3 100.0 85.7 100.0
1,2,3,4-Tetrahydro-1,5,7-trimethyl-naphthalene MS 159 90 66.7 71.4 85.7 81.0
p-Cymene MS 132 97 91.7 100.0 100.0 100.0
Linalyl oxide MS 59 82 83.3 92.9 100.0 90.5
Dihydrolinalool MS 73 84 16.7 28.6 57.1 76.2
Acetic acidb St, MS 43 90 100.0 100.0 100.0 100.0
Furfural St, MS 96 91 100.0 92.9 100.0 100.0
2,6-Dimethyl-7-octen-2-ol St, MS 59 90 91.7 100.0 100.0 100.0
1,2,3,4-Tetramethyl-benzene MS 119 80 50.0 28.6 57.1 66.7
Decanal St, MS 57 86 58.3 85.7 71.4 100.0
Bornylene MS 93 96 83.3 85.7 85.7 71.4
Vitispirane Ib MS 192 82 100.0 100.0 100.0 100.0
Vitispirane IIb MS 192 85 100.0 100.0 100.0 100.0
1,2,3,4-Tetrahydro-1,1,6-trimethyl-naphthalene MS 159 92 91.7 92.9 100.0 100.0
1-Octanol St, MS 56 90 91.7 85.7 71.4 100.0
Menthol MS 71 94 83.3 85.7 57.1 71.4
2-Furanmethanol St, MS 98 80 83.3 78.6 57.1 85.7
2-Methyl butanoic acid St, MS 74 83 91.7 92.9 100.0 81.0
Anisole MS 134 95 83.3 85.7 71.4 71.4
(+)-4-Carene MS 93 80 58.3 64.3 28.6 71.4
2-Methyl-3-phenyl-2-propenal St, MS 145 80 91.7 85.7 100.0 100.0
4-(1-Methylethyl)-1-cyclohexene-4-carboxaldehyde MS 109 85 41.7 42.9 57.1 19.0
3-Carvomenthenone MS 82 80 33.3 42.9 28.6 33.3
D-Carvone MS 82 80 66.7 57.1 57.1 52.4
1,2-Dihydro-1,1,6-trimethyl-naphthaleneb St, MS 157 97 100.0 100.0 100.0 100.0
1-(4-Methylphenyl)ethanone MS 119 94 33.3 28.6 14.3 14.3
1-Decanol MS 56 88 25.0 28.6 14.3 0.0
4-(1-methylethyl)-benzaldehyde MS 133 84 58.3 14.3 57.1 9.5
3,4-Dimethyl-benzaldehydeb MS 133 95 100.0 100.0 100.0 100.0
b-Damascenoneb St, MS 69 86 100.0 100.0 100.0 100.0
p-Cymene-8-ol MS 43 90 66.7 85.7 100.0 100.0
2-Methoxy-phenol St, MS 109 80 91.7 92.9 100.0 66.7
2,7-Dimethyl-quinoline St, MS 157 85 83.3 85.7 85.7 85.7
Hexanoic acid St, MS 60 90 50.0 50.0 71.4 90.5
1-Dodecanol MS 55 89 8.3 7.1 14.3 NF
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metabolomic profile of the oncological group (Figure 4A). The
most abundant metabolites that belonged to these chemical classes
were 4-heptanone, p-tert-butyl-phenol, 2,6-dimethyl-7-octen-2-ol
and 1-ethyl-3,5-diisopropyl-benzene, respectively. The average
areas of these metabolites indicated that when all cancer patients
were combined into a single group, patients with cancer had higher
levels of 3-methyl-3-phenyl-2-propenal, 3-heptanone, p-cymene,
2-methoxythiophene, phenol, 4-methyl-phenol and 1,2-dihydro-1,
1,6-trimethyl-naphthalene than the control group (Figure 4B).
There was an increase in the amounts of all of these chemicals for
all cancer patients when compared with the controls, except
dimethyl disulphide, which was also a major compound that was
identified to be present in the control group individuals.
The fragment ion m/z values of the identified urinary
metabolites with the highest abundance within each fragmentation
pattern, the matching percentage of the NIST library and their
Table 2 (Continued )
Frequency of occurrence (%)
Metabolites IDa m/z Match per cent Colorectal Leukaemia Lymphoma Control
2,6-Dimethyl-naphthalene MS 156 98 100.0 92.9 71.4 76.2
1-Ethyl-3,5-diisopropyl-benzene MS 175 88 100.0 100.0 100.0 NF
Phenolb St, MS 94 91 100.0 100.0 100.0 100.0
Eugenol St, MS 164 92 33.3 28.6 NF NF
Octanoic acid St, MS 60 83 91.7 85.7 85.7 95.2
4-Methyl-phenol St, MS 107 90 100.0 100.0 85.7 95.2
Hexadecanal MS 57 96 33.3 NF 28.6 NF
1,4,5-Trimethyl-naphthalene MS 155 86 66.7 78.6 71.4 57.1
2-Methoxy-4-vinylphenol St, MS 135 80 33.3 42.9 28.6 52.4
Decanoic acid St, MS 60 80 66.7 71.4 71.4 100.0
p-Tert-butyl-phenolb MS 135 96 100.0 100.0 100.0 100.0
2,4-Bis(1,1-dimethylethyl)-phenol MS 191 95 100.0 92.9 85.7 100.0
Benzenecarboxilic acid St, MS 105 90 58.3 64.3 71.4 85.7
Indole MS 117 88 100.0 100.0 100.0 100.0
Abbreviation: NF¼ not found. aMetabolite identification using standard compound (st) or mass spectra of the NIST library search (MS). bMetabolites identified in all 54 studied
subject. cMeans that the metabolite was identified in all subjects of the corresponding group.
Table 3 Potential volatile marker metabolites found in the urinary volatile composition of the four groups by total significance of one-way ANOVA and
LSD post-hoc test for multiple comparisons
Meana values of peak areas (n¼ 3) One-way significance
Metabolites
Colon
(A) %Changeb
Lymphoma
(B) %Change
Leukaemia
(D) %Change
Control
(E) F P-valuec
LSD (multiple
comparison test)
Hexanal 101 409 54.6 125 271 44.0 195 841 12.4 223 543 4.531 0.002 A–E (P¼ 0.016)
Heptanal 17 866 62.3 89 807 89.6 NF NF 47 370 4.084 0.024 A–E (P¼ 0.045)
2-Methyl-3-phenyl-2-propenal 299 264 148.3 653 443 442.2 144 933 20.2 120 528 5.515 0.001 A–B (P¼ 0.012)
B–D (Po0.001)
B–E (Po0.001)
3-Heptanone NF NF 566 713 684.9 NF NF 72 205 16.490 o0.001 B–E (P¼ 0.002)
1,2,4-Trimethylbenzene 82 898 99.2 57 260 37.6 66 229 59.1 41 623 3.124 0.032 A–E (P¼ 0.006)
p-Cymene 1743 047 210.2 1 320 992 135.1 858 328 52.8 561 906 2.741 0.050 A–E (P¼ 0.009)
Anisole 568 939 834.5 14 948 75.4 144 401 137.2 60 881 23.088 o0.001 A–D (Po0.001)
A–E ( Po0.001)
g-Terpinene 499 986 187.2 91 305 47.5 88 595 49.1 174 078 4.041 0.012 A–D (P¼ 0.004)
A–E (P¼ 0.022)
Bornylene 73 702 374.3 3998 74.3 35 962 131.4 15 540 3.131 0.047 A–D (P¼ 0.026)
A–E (P¼ 0.009)
Dimethyl disulphide 3 246 008 52.9 3 789 218 45.0 3 496 595 49.3 6 892 194 4.667 0.005 A–E (P¼ 0.006)
D–E (P¼ 0.008)
2-Methoxythiophene 282 352 14.1 2 767 00 11.9 401 862 62.4 247 376 5.211 0.003 D–E (P¼ 0.005)
4-Methyl-phenol 3 730 154 216.5 1 660 457 40.9 2 232 899 89.4 1178 693 3.776 0.014 A–E (P¼ 0.006)
1-Octanol 64 089 28.8 124 984 38.9 136 895 52.2 89 968 3.562 0.019 A–D (P¼ 0.002)
D–E (P¼ 0.021)
1,2-Dihydro-1,1,
6-trimethyl-naphthalene
2 092 233 189.0 760 528 5.1 1 316 780 81.9 723 911 3.571 0.018 A–E (P¼ 0.002)
1,4,5-Trimethyl-naphthalene 75 610 131.7 51 364 57.4 37 398 14.6 32 634 4.136 0.011 A–D (P¼ 0.006)
A–E (P¼ 0.002)
2,7-Dimethyl-quinoline 326 614 268.1 113 090 27.5 85 692 3.4 88 718 5.697 0.002 A–D (P¼ 0.002)
A–E (P¼ 0.001)
Abbreviations: ANOVA¼ analysis of variance; LSD¼ least significant difference; NF¼ not found; r.s.d.¼ relative standard deviation. aAverage value from three replicates; r.s.d.
lower than 20%. bPercentage change of cancer from normal, calculated from the arithmetic mean values of each group. Positive and negative percentages indicate higher levels of
metabolites in cancer patients and healthy subjects, respectively. cStatistical P-value calculated using the LSD test (significance at Po0.05).
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frequency of occurrence in cancer patients and normal controls are
listed in Table 2.
Among the 82 total metabolites identified, 21 were found in all
(patients and controls) of the individuals who submitted to this
study. As can be seen in Table 2, of the 82 identified metabolites,
only 27 were common to colorectal cancer patients, whereas in the
leukaemia and lymphoma cancer patients, the total number of
common metabolites was 28 and 36, respectively. 3-Heptanone was
only detected in half of the lymphoma patients, whereas 4-methyl-
2-heptanone was only identified in colorectal patients (84%).
One-way ANOVA with Pvalueso0.05 was achieved for both
groups (oncological and control) using SPSS, version 17.0. The
positive rates of all 82 volatile metabolites were compared between
the cancer group and the control group. Of the 82 identified
metabolites, 16 were statistically significant (ANOVA, Po0.05)
between the cancer patient and control groups, whereas the others
did not show any significant differences. These volatile metabolites
are summarised in Table 3.
Of the 16 metabolites of interest, it can be see that 3-heptanone,
anisole, 2-methyl-3-phenyl-2-propenal, 2,7-dimethyl-quinoline
and hexanal had the lowest P-values. If we looked more closely
at the peak areas (Table 3), the urinary levels of 2-methyl-3-
phenyl-2-propenal, 3-heptanone and anisole that were found in
healthy volunteers were much lower than those found in cancer
patients. On the other hand, the urinary levels of hexanal and
dimethyl disulphide were much higher in healthy persons than in
cancer patients (Figure 5).
Metabolomic differences between the different types of inves-
tigated cancers were also detected (Figure 5). Such differences were
manifested as higher levels of 2-methyl-3-phenyl-2-propenal and
3-heptanone and lower levels of aldehydes (hexanal and heptanal)
in the lymphoma cancer patients in comparison with colorectal
and leukaemia patients. Furthermore, urinary levels of p-cymene,
anisole, g-terpinene, bornylene, dimethyl disulphide, 4-methyl-
phenol, 1,2-dihydro-1,1,6-trimethyl-naphthalene, 1,4,5-trimethyl-
naphthalene and 2,7-dimethyl-quinoline were higher in colorectal
patients than in lymphoma and leukaemia patients. In addition,
the increased content of sulphur-containing metabolites, namely
2-methoxythiophene and dimethyl disulphide, in leukaemia patients
were statistically significant in comparison with normal controls
(Figure 5).
The high inter-individual variability in urinary profiles and their
complexity make any attempt at visual comparison of these spectra
an unproductive task. Instead, multivariate analysis allowed the
finding of consistent variation patterns within the data set. To
study the principal sources of variation among the results, detect
intrinsic clustering and possible outliers, and distinguish cancer
patients from healthy individuals, exploratory PCA was applied to
the GC-qMS peak areas that were obtained for the urinary volatile
metabolites of both groups. This PCA is an unsupervised
projection method that is used to visualise the data set and
display similarities and differences. After preliminary statistical
analysis, the PCA of the data showed that the variables described in
Table 3 were enough to describe subsets with similar character-
istics and relate to the health status of the subjects. Figure 6A
depicts the loadings of 16 variables on a plane defined by the first
(PC1) and second (PC2) principal components.
Although this set of variables only explained 88.77% of the
variability between the first two PCs, it was enough to deconvolute
the set of cases in four subsets according to the health of the
subjects and to cancer type. These results indicate a significant
potential of early diagnosis of the studied cancer types using non-
invasive urinary metabolomic analysis (Figure 6B).
The scores of the scatter plot demonstrate that PC2, which
contained 25.13% of the total variability, split the samples into
three different groups. The group located among the PC2-positive
values corresponded to patients with lymphoma, whereas the
second group, located among the negative values from PC1 and
PC2, contained the leukaemia patients and normal controls. The
third group, located among the PC1-positive and PC2-negative
values, comprised the samples corresponding to the colorectal
cancer subjects. These results demonstrate that the set of cases
could be divided into four groups according to the clinical
condition of the subjects.
The chemicals 3-heptanone (ZHept3), dimethyl disulphide
(ZDisslf) and heptanal (ZHept) appear to play an important role
in the healthy individuals group (control) and leukaemia patients.
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Figure 6 Separation of cancer patients and healthy individuals based on principal component analysis (PCA) scores scatter plot. (A) Loadings of variables
on the PC1–PC2 plane (88.77% of total variance). (B) Factor scores for PCA analysis showing the similarity groups for healthy persons (control group), and
cancer patients as described by variables represented in Figure 4A.
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Figure 5 Percentage of change between cancer patients and normal
subjects. Numbered bars correspond to: (1) hexanal; (2) heptanal; (3) 2-
methyl-3-phenyl-2-propenal; (4) 3-heptanone; (5) 1,2,4-trimethylbenzene;
(6) p-cymene; (7) anisole; (8) g-terpinene; (9) bornylene; (10) dimethyl
disulphide; (11) 2-methoxythiophene; (12) 4-methyl-phenol; (13) 1-octanol;
(14) 1,2-dihydro-1,1,6-trimethyl-naphthalene; (15) 1,4,5-trimethyl-naphtha-
lene; and (16) 2,7-dimethyl-quinoline.
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Colorectal cancer patients appear to be better characterised by
1,4,5-trimethyl-naphthalene (ZTnaft), 2,7-dimethyl-quinoline
(ZDmql) and 2-methyl-3-phenyl-2-propenal (ZMet3fen). The
chemicals 1-octanol (ZOct1), hexanal (ZHex) and 2-methoxythio-
phene (ZMetox) correlated well with the lymphoma subjects.
CONCLUSIONS
In this study, dHS-SPME/GC-qMS-based metabolomics was
applied to investigate urinary cancer volatile metabolites as a
useful tool to evaluate volatile metabolites for the early diagnosis
of cancer. We found that dHS-SPME combined with GC-qMS was a
simple, rapid, sensitive and solvent-free method that is highly
suitable for this purpose. The potential advantages of urine
analysis over other conventional medical tests include its non-
invasive nature, low cost and safety. To achieve the highest
recovery rate, the isolation procedure was optimised via the
selection of an appropriate fibre, extraction temperature and
extraction time using univariate optimisation design. A CAR/
PDMS fibre was found to be more sensitive for volatile metabolites
than other coating phases. In all, 82 volatile metabolites were
detected and identified in the control and oncological groups
belonging to distinct chemical families, including aldehydes,
ketones, terpenoids, acids, alcohols, benzene derivatives, furans
and sulphur compounds, phenols, esters and naphthalene
derivatives. Some of the metabolites were of endogenous origin
and generated in the human body during normal metabolic
processes, whereas some were inhaled with subsequent storage and
later exhalation/excretion.
For the control group, the chemical families with the higher
contributions to the urinary metabolomic profile were ketones and
sulphur compounds. The major metabolites of these chemical
families were 4-heptanone and methanethiol. Benzene derivatives,
terpenes and volatile phenols were the chemical classes that
exhibited higher contributions to the metabolomic patterns that
were identified in the oncological group. Different VOM profiles
for healthy people and cancer patients could be recognised by
multivariate analysis, and significant diagnostic compounds could
be established. Between the cancer group (n¼ 33) and the control
group (n¼ 21), positive rates for 16 of the 82 detected compounds
were found to be different with statistical significance (Po0.05,
LSD test). There were definitive metabolomic differences between
cancer patients and healthy individuals and between different
types of cancer. The identification of volatile biomarkers in urine
for disease diagnosis is an area of great promise, but it is based on
limited previous human research. The data in this paper are
consistent with the hypothesis that diagnostically useful volatile
compounds are produced in patients with cancer and secreted into
the urine, thus providing support for this diagnostic approach. The
ability to easily collect and store urine samples will be a major
advantage of this approach.
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